News & Updates

Patients with postacute COVID-19 syndrome (PACS) may benefit from faecal microbiota transplantation (FMT) treatment, which helps reduce anxiety and improve sleep quality, suggests a study.

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Overuse of short-acting β2 agonists (SABA) is prevalent among patients with asthma in Hong Kong and associated with an increased risk of all-cause mortality and hospital admissions, according to a local retrospective cohort study, which was part of the global SABINA (SABA Use in Asthma) research programme.

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.

Although the COVID-19 pandemic is over, the disease remains a threat as it is predicted to become a significant danger to public health in the next 2 years, particularly in the US, according to a study. Wide-ranging vaccination, however, can counter this potential problem.